Based on these findings, we established a risk signature comprised of CD276, TNFRSF14, TNFSF14, TNFSF4, CD40, and TNFRSF18 to predict OS and response to immune checkpoint blockade in glioblastoma patients. The gene discussed is TNFRSF18; the disease is glioblastoma.